Status:
UNKNOWN
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Lead Sponsor:
Department of Veterans Affairs, New Jersey
Collaborating Sponsors:
Pfizer
Sanofi
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to find out the safety and effectiveness as well as patient's quality of life on the combination of Taxotere and celecoxib on patients with hormone refractory pro...
Detailed Description
The standard hormone therapy for patients with metastases is androgen deprivation. This treatment leads to response in 75-80% of the patients, with median duration of response of only 14-18 months. On...
Eligibility Criteria
Inclusion
- Patient must have histologically proven adenocarcinoma of the prostate gland.
- Patient must have evidence of progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or lung metastases) within 6 weeks prior to participation in the study.
- Patients who have evaluable but not measurable disease must not have an elevated PSA level as the only evidence of disease. While castrated, the patients should have rising PSA on two consecutive measurements at least 1 week apart. The confirmatory PSA must be obtained within 1 week prior to study registration and should be \>10ng/ml.
- Patients with bone metastases only (i.e., lacking soft-tissue disease) must have a PSA level of \> 10 ng/ml. Patients with soft tissue metastases and /or visceral disease must have either measurable disease or a PSA level of \> 10 ng/ml.
- Radiological evidence of hydronephrosis will not by itself constitute evidence of metastatic disease.
- Patients must have had prior treatment with bilateral orchiectomy or other primary hormonal therapy (e.g., estrogen therapy, LHRH analog + flutamide, etc.) with evidence of treatment failure.
- NOTE: patients who have not undergone bilateral orchiectomy must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) while receiving this protocol therapy. For these patients the testosterone level should be preferably checked before enrollment and should be \< 50 ng/dl.
- For patients previously treated with flutamide (Eulexin), nilutamide (Nilandron), or bicalutamide (Casodex): Patients must have discontinued flutamide or nilutamide \< 4 weeks and for bicalutamide 6 weeks prior to registration.
- Patients must not have received prior treatment with chemotherapy within the last 5 years.
- Patients must not have had prior radiotherapy \< 4 weeks prior to this protocol treatment.
- Patients must not have previously received Strontium 89, Samarium 153, or other radioisotope therapies.
- Patients must have recovered from all toxicities due to prior treatment for prostate cancer prior to receiving this protocol treatment.
- Patients must have adequate bone marrow function: (WBC \> 4000/ mm3, granulocytes \> 1500/ mm3, platelet count \> 100,000/mm3, and Hemoglobin \> 8.0 g/dl \< 4 weeks prior to participate in this study.
- Patients must have the following chemistry values \< 4 weeks prior to participate in this study:
- Total bilirubin must be within normal limits.
- Creatinine \< 2.0 mg/d. or creatinine clearance \> 50 ml/min
- Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphastase is \< ULN, or alkaline phosphastase may be up to 4 x ULN if transaminases are \< ULN.
- Peripheral neuropathy must be \< grade 1
- Patients must have no active angina pectoris, or known heart disease of New York Heart Association Class III-IV. Patients must not have a history of myocardial infarction \< 6 months prior to the study participation.
- Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for the specific cancer.
- No serious concurrent medical illness or active infection should be present which would jeopardize the ability of the patient to receive the chemotherapy outlined in this protocol with reasonable safety.
- Sexually active patients must use an accepted and effective method of contraception while receiving protocol treatment.
- Patients must have a Karnofsky Performance Scale (KPS) score over 50. (equaling ECOG Performance Scale of 0, 1, or 2).
- Age \> 18 years
Exclusion
- Patients with a history of severe hypersensitivity to Taxotere or other drugs formulated with polysorbate 80 must be excluded
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00215345
Start Date
August 1 2002
End Date
December 1 2006
Last Update
September 22 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department Of Veterans Affairs NJ Health Care System
East Orange, New Jersey, United States, 07018